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ABSTRACT 
Objective: Simple and sensitive an extractive-spectrophotometric method have been developed for the determination of four important 
antihistaminic drugs, namely desloratadine (DSL), chlorpheniramine maleate (CPM), diphenhydramine hydrochloride (DPH) and fexofenadine 
(FXO).  
Methods: This method is based on the formation of colored ion-pair complexes between the basic nitrogen of the drugs and halofluorescein dyes, 
namely rose bengal (RB) dye in weak acidic medium. The formed complexes were extracted with dichloromethane measured 
spectrophotometrically at 550 nm. 
Results: The reaction conditions were optimized to obtain the maximum color intensity. Beer’s law was obeyed with a good correlation coefficient 
(0.9963-0.9975) in the concentration ranges 1-6, 4-18, 6-16 and 2-22 µg/ml for DSL, CPM, DPH and FXO, respectively. The composition ratio of the 
ion-pair complexes was found to be 1:1 as established by Job’s method. 
Conclusion: The proposed method was successfully extended to pharmaceutical preparations. Excipients used as additive in commercial 
formulations did not interfere in the analysis. The proposed method can be recommended for quality control and routine analysis where time, cost 
effectiveness and high specificity of analytical technique are of great importance. 




Desloratadine (DSL, fig. 1), 4-(8-chloro-5,6-dihydro-11H-benzo-
[5,6]cyclohepta [1,2b]pyridin-11-ylidene)-1-piperidine. DSL is a 
selective peripheral H1 receptor antagonist, devoid of any 
substantial effect on the central and autonomic nervous systems [1, 
2]. Desloratadine exhibits qualitatively similar pharmacodynamic 
activity with a relative oral potency in animals, two to three-fold 
greater than its parent analogue loratadine, probably due to a higher 
affinity for histamine H1 human receptors [3].  
Several analytical methods have been reported for the 
determination of DSL in biological samples and applied in 
pharmacokinetics studies. These methods include liquid 
chromatography [4-6] and High-performance liquid 
chromatographic method [7]. However, DSL was determined in 
pharmaceutical preparations using a spectrophotometric and 
spectrofluorometric [8-12]. 
Chlorpheniramine maleate (CPM, fig. 1), ((3-(4-chloro-phenyl)-N,N-
dimethyl-3-(2-pyridyl)propylaminemonomaleate) 1), chemical 
structure is showed in (fig. 1c). Chlorpheniramine maleate is an 
antihistamine drug that is widely used in phamarceutical 
preparations for symptomatic relief of common cold and allergic 
diseases [13]. Chlorpheniramine maleate was determined in 
pharmaceutical dosage forms and plasma samples by 
chromatographic [14-24], spectrophotometric [25-28] and 
electrochemical methods [29, 30]. 
Diphenhydramine hydroch loride (DPH, fig. 1), is an antihistamine 
drug having the chemical name 2-(diphenylmethoxy)-N,N-
dimethylethylamine hydrochloride. It is usually administered orally 
and may be used by intramuscular or intravenous injection in severe 
allergies and applied topically for local allergic reactions. Several 
published methods have been developed for the determination of 
DPH in pharmaceutical preparations and in biological fluids 
including: spectrophotometry [31–34], flow injection analysis [35], 
gas chromatography [36], atomic absorption spectrometry [37], high 
performance liquid chromatography [38], Liquid chromatography 
[39] and capillary electrophoresis [40–42].  
Fexofenadine (FXO, fig.1) is, chemically, 2,2-dimethyl-4(1-hydroxy-4-
{hydroxy diphenylmethyl-1-piperidinyl}butyl)benzoaceticacid. FXO is 
a highly selective peripheral histamine H1 receptor antagonist used in 
the treatment of allergic diseases such as allergic rhinitis and chronic 
urticaria. Fexofenadine is the active derivative of the antihistamine 
terfenadine, with no antichrolinergic or alpha 1-adernergic receptor-
blocking effects and without severe cardiac side effects of terfenadine 
[43, 44]. Several methods for the determination of fexofenadine 
hydrochloride in pharmaceutical formulations and biological fluids 
have been reported including chromatographic methods [45–52], 
spectrophotometry [53–58], spectrofluorometry [59], potentiometry 
[60], and capillary electrophoresis [61].  
The proposed method is dedicate to study the formation of a ion-
pair complex between each of the studied drugs and rose bengal dye 
in an attempt to develop a simple, sensitive and accurate extraction-
free spectrophotometric method for the determination of DSL, CPM, 
DPH and FXO drugs in their pharmaceutical preparations. 
MATERIALS AND METHODS 
Equipments 
All the absorbance spectral measurements were made using spectroscan 
80 D double-beam UV/Visible spectrophotometer (Biotech Sedico, 
Scientific Equipment Distribution, Ltd. Nicosia, Cyprus), with wavelength 
range 190 nm ~ 1100 nm, spectral bandwidth 2 nm, with 10 mm 
matched quartz cells. An Orion Research Model 601 A/digital analyzer, 
pH-meter with a combined saturated calomel glass electrode was used 
for pH measurements, water bath and hot plate. 
Materials 
All chemicals and reagents were of pharmaceutical or analytical 
grade and all solutions were prepared fresh daily. They are included 
drugs under investigation: desloratadin (DSL) chlorpheniramine 
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(CPM), diphenhydramine (DPH) and fexofenadine (FXO) that 
supplied from Egyptian International Pharmaceutical Industries 
Company (EIPICo) 10th of Ramadan City, Egypt. Rose bengal was 
supplied from (Aldrich), sodium acetate and methylene chloride 
were supplied from (Egyptian, Adewic).  
Tablets containing the drugs were obtained from the local market. 
The pharmaceutical preparations of desloratadine pharmaceutical 
preparations were delarex tablets 5 mg/tab produced by (global 
napi Pharm. Cairo–Egypt). The chlorpheniramine maleate 
pharmaceutical preparations were anallerge tablets 4 mg/tab 
(Kahira Pharm. Cairo–Egypt). Diphenhydramine hydrochloride is 
sultan tablets, 50 mg/tab produced by Pharaonia pharmaceuticals. 
The fexofenadine hydrochloride pharmaceutical preparations were 





Desloratadine (DSL) Chlorpheniramine maleate (CPM) 
  
Diphenhydramine hydrochloride (DPH) Fexofenadine hydrochloride (FXO) 
Fig. 1: Chemical structures of the studied drugs 
 
Reagents and solutions  
All chemicals and reagents used were of analytical-reagent grade 
and distilled water was used throughout the investigation.  
Pure drugs 
An accurately weighed quantity of the investigated drugs (20 mg) 
was dissolved in distilled water in a 100 ml measuring flask. Aliquots 
of the above prepared stock solution were further diluted to obtain 
100 µg/ml working standard solutions. 
Buffer solution 
Citrate–phosphate buffer was prepared by adding 0.20 M disodium 
hydrogen phosphate (Fisher Scientific Co., Pittsburgh, PA) to 50 ml 
0.1 M citric acid (Sigma Chemical Co., St. Louis, MO) to adjust the pH 
to 2–7 and the volumes were diluted to 100 ml with distilled water. 
Dye stuff 
A stock solution of 1×10-3
Procedure for calibration curves 
M rose bengal {4,5,6,7-Tetrachloro-3',6'-
dihydroxy-2',4',5',7'-tetraiodo-3H-spiro[isobenzofuran-1,9'-
xanthen]-3-one}, was prepared by dissolving 97.367 mg from dye 
(99% purity) in distilled water and diluting to 100 ml in a measuring 
flask with distilled water. 
Into a series of separating funnels, accurately measured aliquots 
DSL, CPM, DPH or FXO in the concentration range shown in (table 1) 
were pitted out and then 2.0 ml of 1×10-3
Procedure for tablets 
M of RB dye was added. The 
solution was diluted to 10 ml with distilled water after the addition 
of 2.0 ml of acetate buffer of pH 6 for CPM, DPH or FXO but buffer of 
pH 6.8 for DSL was added. The ion-pairs were extracted with 10 ml 
of dichloromethane by shaking for 2.0 min and then, the combined 
dichloromethane extracts were dried over anhydrous sodium 
sulphate. The absorbance of colored ion-pair complexes were 
measured within 5.0 min of extraction against the reagent blank 
prepared in the same manner except addition of drugs.  
Ten tablets of each commercial pharmaceutical formulation were 
crushed, powdered, weighed out and the average weight of one 
tablet was determined. An accurate weight equivalent to 20 mg each 
drug and then active component was transferred into a 100 ml 
measuring flask. About 25 ml of distilled water was added and the 
mixture was shaken thoroughly for about 5 min. Then, it was diluted 
up to the mark with distilled water, mixed well and filtered using 
filter paper. An aliquot of this solution was diluted appropriately to 
obtain the working concentrations and analyzed as described under 
the standard procedure. 
RESULTS AND DISCUSSION 
Absorption spectra 
The absorption spectra of the ion-pair complexes were measured in 
the range 525-630 nm against dichloromethane (blank). 
Antihistamine cations were found to react with anions of rose bengal 
dye in acidic buffer and gave an intense color with a maximum 
absorption at 550 nm as shown in fig. 2. Therefore, all the following 
measurements are carried out at 550 nm against blank where the 
investigated drugs, dyes, buffer and dichloromethane have no 
absorption in this region. The optimum conditions were established 
by varying one variable and observing its effect on the absorbance of 
the colored product. 
 
 
Fig. 2: Absorption spectra of 6 µg/ml DSL with RB dye at pH = 6.8 
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Effect of pH 
The influence of pH on the ion-pair complex formations of DSL, CPM, 
DPH and FXO with RB dye has been studied using different types of 
buffers of different media. The optimum buffer associated with the 
maximum color intensity is disodium hydrogen phosphate-citric 
acid of pH=6 in case of DPH, CPA or FXO but pH=6.8 in case of DSL 
(fig. 3). Buffer volume was determined by applying the same 
experiment and variation the volume regularly (0.5-4.0 ml). The 






Fig. 3: Effect of pH on the formation of ion-pair complex 
between RB and the studied drugs at 550 nm 
 
Choice of organic solvent  
A number of organic solvents such as dichloromethane, chloroform, 
carbon tetrachloride, benzene and toluene were examined for 
extraction of the ion-pair complexes in order to provide an 
applicable extraction procedure. Dichloromethane was found to be 
the most suitable solvent for extraction of colored complex yielding 
maximum absorbance intensity and it was also, observed that only 
one extraction was adequate to achieve a quantitative recovery of 
the complex and very low absorbance of the reagent blank and 
shortest time to reach the equilibrium between both phases. 
Effect of RB dye concentration 
Keeping other conditions unaltered, the influence of 1×10-3
Effect of shaking time 
M RB dye 
concentration on absorbance was investigated. The results showed 
that the maximum absorbance was at using 3.0 ml from RB dye for 
DSL, CPM, DPH and FXO. After this volume, the absorbance remains 
constant by increasing the volume of RB dye. So any excess of 
reagents has no effect on the determination of the drugs. 
Shaking time of 1.0-4.0 min provided a constant absorbance and 
hence, 2.0 min was used as an optimum shaking time throughout the 
experiment. The ion-pair complexes were quantitatively recovered 
in one extraction only and were, also stable for at least 24 h without 
any change in color intensity.  
Sequence of addition 
The sequence of addition of drugs, buffer, and dye were studied via 
the formation of the colored complexes. The optimum sequence of 
addition was similar in all cases by starting with drug, then dye and 
at last buffer. Other sequences gave lower absorbance values under 
the same experimental conditions. 
Effect of temperature and stability time 
The effect of temperature on colored complexes was studied over 
the range 20-35 °C. It was found that the absorbance of the ion pair 
complex was constant up to 30 °C. At higher temperatures, the drug 
concentration was found to increase due to volatile nature of the 
dichloromethane. Therefore, the temperature chosen was 30 °C as 
the best temperature for micro-determination of the drugs under 
study in pure and pharmaceutical formulations. The stability time of 
the four extracted ion-pair complexes was more than 120 min. 
Stoichiometric ratio 
In order to establish the molar ratio between DSL, CPM, DPH, FXO 
drugs on one side and RB reagent used on the other, Job’s method of 
continuous variation was applied [62]. In this method, 5×10-3 M 
solutions of drug and reagent were mixed in varying volume ratios 
in such a way that the total volume of each mixture was the same. 
The absorbance of each solution was measured and plotted against 
the mole fraction of the drug. This procedure showed that a (1: 1) 
complex was formed through the electrostatic attraction between 
the positively charged drug, D+ions and negatively charged reagent, 
R-
Daq+ + Raq−  ↔ D+Raq−  ↔ D+Rorg−  
, ions. The extraction equilibrium can be represented as follows:  
Where D+and R-
Quantification 
represent the protonated drug and the anion of the 
reagent, respectively and the subscripts “aq” and “org” refer to the 
aqueous and organic phases, respectively.  
Under the optimum conditions described above, the calibration graphs 
for the investigated drugs were constructed by plotting absorbance 
versus concentration in μg/ml. (fig. 4). Conformity with Beer's law was 
evident in the concentration ranges cited in table 1. Regression 
equations, intercepts, slopes and correlation coefficients for the 
calibration data were presented in table 1.  
The high molar absorptivities of the resulting colored complexes 
indicated high sensitivity of the method (2.35×104–6.28×104
 
). The small 
values of Sandell's sensitivity indicate the high sensitivity of the 
proposed method in the determination of the drugs under investigation. 
The limit of detection (LOD) and limit of quantitation (LOQ) are 
calculated according to ICH guidelines [63] and the results are tabulated 
in (table 1). 
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Fig. 4: Calibration curves for determination of: DSL (1–6 µg/ml), 
CPM (4–18 µg/ml), DPH (6–16 µg/ml) and FXO (2–22 µg/ml) 
under optimum conditions 
 
Accuracy and precision 
In order to determine the accuracy and precision of the 
recommended procedure five replicate determinations at three 
different concentrations of the studied drugs were carried out. 
Precision and accuracy were based on the calculated relative 
standard deviation (RSD, %) and relative error (RE, %) of the found 
concentration compared to the theoretical one, respectively and 
indicate that the proposed method is highly accurate and 
reproducible (table 2). 
 
Table 1: Analytical parameters and optical characteristics with RB dye 
Parameters Drugs 
DSL CPM DPH FXO 
ƛmax 550 (nm) 550 550 550 
pH 6.8 6 6 6 
Beer’s law limit, µg/ml 1-6 4-18 6-16 2-22 
Molar absorptivity, l mol-1 cm 6.28×10-1 2.69×104 2.35×104 2.84×104 
Sandell’s sensitivity, ng/cm
4 
4.94 2 14.52 12.41 18.90 
Correlation coefficient (r) 0.9938 0.9945 0.9947 0.9926 
Linear regression equation  *    
S 0.0214 y/x 0.0278 0.0167 0.0225 
Intercept (a) 0.4214 0.0563 0.3860 0.5063 
Slope (b) 0.1284 0.0668 0.0550 0.0312 
S. D. of slope (Sb 5.13×10) 2.38×10-3 1.99×10-3 1.34×10-3 
S. D. of intercept (S
-3 
a 0.0440 ) 0.0584 0.0538 0.0395 
LOD, µg/ml 0.0155 0.0299 0.0363 0.0641 
LOQ, µg/ml 0.0518 0.0997 0.1210 0.2134 
P
*
PA= a+bC, where A is the absorbance and C is the concentration of drug in µg/ml. 
 
Table 2: Evaluation of intra-day accuracy and precision of the proposed method 
Drugs Drug taken μg/ml Drug foundPaP  μg/ml Recovery, % RSD,  % RE PbP,  % 
DSL 1.0 0.999 99.994 3.410 -0.100 
3.0 2.999 99.996 2.104 -0.033 
5.0 4.999 99.994 1.152 -0.020 
CPM 4.0 3.999 99.996 4.255 -0.025 
8.0 7.999 99.994 6.075 -0.012 
14 13.999 99.996 2.542 -0.007 
DPH 2.0 1.999 99.994 4.214 -0.050 
6.0 5.999 99.994 1.401 -0.016 
10 9.999 99.996 1.759 -0.010 
FXO 2.0 1.999 99.996 3.871 -0.050 
10 9.999 99.994 0.994 -0.010 
18 17.999 99.996 3.759 -0.005 
P
a
PMean value of five determinations, Pb PRE: Relative error. 
 
Analysis of dosage forms 
To evaluate the validity and reproducibility of the method, known 
amounts of the DSL, CPM, DPH and FXO drugs were added to the 
previously analyzed pharmaceutical preparations and the mixtures 
were analyzed by the proposed method. The percent recoveries are 
given in table 3. Interference studies revealed that the common 
excipients and other additives such as lactose, starch, gelatin, talc 
and magnesium trisilicate, that are usually present in the tablet 
dosage forms did not interfere at their regularly added levels.
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Table 3: Recovery of the studied drugs in pharmaceutical formulations using the proposed method 
Drug formulations Drug taken μg/ml Drug foundPaP  μg/ml Recovery, % RSD,  % RE PbP,  % 
sultan tablets, 
50 mg/tab 
2 1.999 99.994 1.232 -0.050 
6 5.999 99.994 1.761 -0.016 
10 9.999 99.999 2.929 -0.010 
anallerge tablets,  
4 mg/tab 
4 3.999 99.994 4.134 -0.025 
8 7.999 99.996 2.910 -0.012 
14 13.999 99,994 1.579 -0.007 
allerfen tablets, 
60 mg/tab 
6 5.999 99.994 4.762 -0.016 
14 13.999 99.996 2.936 -0.007 
18 17.998 99.994 2.375 -0.011 
delarex tablets, 
5 mg/tab 
2 1.999 99.994 4.377 -0.050 
4 3.999 99.996 3.466 -0.025 
5 4.999 99.996 3.811 -0.020 
P
a
PMean value of five determinations, Pb PRE: Relative error. 
 
CONCLUSION 
The proposed spectrophotometric method is simple, sensitive, and 
suitable for the determination of DSL, CPM, DPH and FXO drugs in 
bulk and pharmaceutical dosage forms. The proposed method offers 
the advantages of accuracy and time saving as well as simplicity of 
reagents and apparatus. The developed method may be 
recommended for routine and quality control analysis of the 
investigated drugs in pharmaceutical preparations. 
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